C
Chelsea Caspell-Garcia
Researcher at University of Iowa
Publications - 46
Citations - 2403
Chelsea Caspell-Garcia is an academic researcher from University of Iowa. The author has contributed to research in topics: Medicine & Parkinson's disease. The author has an hindex of 20, co-authored 38 publications receiving 1372 citations.
Papers
More filters
Journal ArticleDOI
The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort
Kenneth Marek,Sohini Chowdhury,Andrew Siderowf,Shirley Lasch,Christopher S. Coffey,Chelsea Caspell-Garcia,Tanya Simuni,Danna Jennings,Caroline M. Tanner,John Q. Trojanowski,Leslie M. Shaw,John Seibyl,Norbert Schuff,Andrew B. Singleton,Karl Kieburtz,Arthur W. Toga,Brit Mollenhauer,Doug R. Galasko,Lana M. Chahine,Daniel Weintraub,Tatiana Foroud,Duygu Tosun-Turgut,Kathleen L. Poston,Vanessa Arnedo,Mark Frasier,Todd Sherer,Parkinson's Progression Markers Initiative +26 more
TL;DR: The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease progression markers to accelerate disease‐modifying therapeutic trials.
Journal ArticleDOI
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Daniel Weintraub,Tanya Simuni,Chelsea Caspell-Garcia,Christopher S. Coffey,Shirley Lasch,Andrew Siderowf,Dag Aarsland,Paolo Barone,David J. Burn,Lama M. Chahine,Jamie L. Eberling,Alberto J. Espay,Eric D. Foster,James B. Leverenz,Irene Litvan,Irene H. Richard,Matthew D. Troyer,Keith A. Hawkins +17 more
TL;DR: This study was undertaken to determine the prevalence and correlates of cognitive impairment and neuropsychiatric symptoms in early, untreated patients with Parkinson's disease.
Journal ArticleDOI
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
Ju-Hee Kang,Ju-Hee Kang,Brit Mollenhauer,Christopher S. Coffey,Jon B. Toledo,Daniel Weintraub,Daniel Weintraub,Douglas Galasko,David J. Irwin,Vivianna M. Van Deerlin,Alice Chen-Plotkin,Chelsea Caspell-Garcia,Teresa Waligorska,Peggy Taylor,Nirali Shah,Sarah Pan,Pawel Zero,Mark Frasier,Kenneth Marek,Karl Kieburtz,Danna Jennings,Caroline M. Tanner,Tanya Simuni,Andrew B. Singleton,Arthur W. Toga,Sohini Chowdhury,John Q. Trojanowski,Leslie M. Shaw +27 more
TL;DR: The data suggest that the measurement of CSF biomarkers in early-stage PD patients may relate to disease heterogeneity seen in PD, and longitudinal observations in PPMI subjects are needed to define their prognostic performance.
Journal ArticleDOI
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
Tanya Simuni,Andrew Siderowf,Shirley Lasch,Christopher S. Coffey,Chelsea Caspell-Garcia,Danna Jennings,Caroline M. Tanner,John Q. Trojanowski,Leslie M. Shaw,John Seibyl,Norbert Schuff,Andrew B. Singleton,Karl Kieburtz,Arthur W. Toga,Brit Mollenhauer,Doug R. Galasko,Lana M. Chahine,Daniel Weintraub,Tatiana Foroud,Duygu Tosun,Kathleen L. Poston,Vanessa Arnedo,Mark Frasier,Todd Sherer,Sohini Chowdhury,Kenneth Marek +25 more
TL;DR: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD.
Journal ArticleDOI
How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?
Tanya Simuni,Chelsea Caspell-Garcia,Christopher S. Coffey,Shirley Lasch,Caroline M. Tanner,Ken Marek +5 more
TL;DR: TD versus PIGD subtype classification has substantial variability over first year in PD de novo cohort specifically for PIGd subtype, and dopaminergic therapy does not impact the change of the PD subtype.